Zacks Investment Research
29 Jun 2026, 18:41 UTC · 2h ago
GMED vs. MDT: Which Medical Stock Has More Upside Potential?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
29 Jun 2026, 18:41 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Globus Medical reported 27% year-over-year revenue growth in the first quarter of 2026. — Strong double-digit top-line growth indicates significant market share gains and product demand.
+0.60Globus Medical's Trauma revenues increased by 30.4% in Q1 2026, driven by the Precice limb lengthening portfolio and ANTHEM Elbow. — High growth in a specific product segment suggests successful diversification and strong competitive positioning.
+0.50Medtronic reported 9.9% year-over-year revenue growth in its fiscal fourth quarter. — Steady growth for a large-cap player is positive, though less explosive than smaller competitors.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Globus Medical is increasing R&D spending, with expectations of 5-6% of net sales for the full year. — Increased R&D spend can weigh on short-term margins but supports long-term pipeline growth.
Which stocks this story touches
The company outperformed the industry with 46.1% share gains and 27% year-over-year revenue growth.
The company outperformed the industry with a 7.6% share gain and 9.9% year-over-year revenue growth.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Business Wire
58m ago
